Vidac Pharma Holding PLC Highlights Compassionate‑Use Case at Eilat Symposium
Vidac Pharma Holding PLC (XETRA: T9G, ISIN: GB00BM9XQ619, WKN: A3DTUQ) announced on 3 March 2026 that it presented a Compassionate‑Use case involving its lead drug candidate VDA‑1102 at the Eilat Symposium on Paediatric Cancer. The case concerned a four‑year‑old girl with a relapsing ependymoma who was scheduled for a third brain surgery.
Clinical Intervention
- Pre‑operative administration: A specific formulation of VDA‑1102 was given under Compassionate‑Use prior to surgery.
- Post‑operative regimen: The treatment continued subcutaneously for one month at a daily dose of approximately 10 mg/kg body weight.
- Objective: Stabilisation of the tumour’s hyper‑glycolytic metabolism and modulation of the tumour micro‑environment to prepare for subsequent surgical and radiotherapeutic interventions.
- Outcome: Both the surgery and the radiotherapy were reported as successful.
Strategic Implications
Vidac Pharma focuses on discovering and developing medicines for oncologic and dermatologic conditions. The Eilat presentation demonstrates the company’s ability to translate pre‑clinical findings into compassionate‑use applications, potentially accelerating clinical development timelines.
The announcement follows the company’s broader positioning in the emerging field of metabolic oncology, where Vidac Pharma seeks to offer therapies beyond symptom control. This aligns with market projections that anticipate significant growth in the treatment of actinic keratosis, a sub‑segment of oncologic dermatology, where the company’s innovations could provide a new therapeutic class.
Market Context
- Current share price: €0.738 (closing 2 March 2026).
- 52‑week range: €0.45 – €0.96.
- Currency: EUR.
Vidac Pharma’s presentation at the Eilat Symposium reinforces its commitment to developing targeted therapies for rare and high‑needs paediatric tumours while positioning itself for future expansion in metabolic oncology and dermatologic oncology markets.
